PONATINIB, an FDA-approved BCR-ABL/VEGFR kinase inhibitor, binds the MSH3 ATPase Walker-A pocket with high affinity — a repurposing candidate to suppress somatic CAG-repeat expansion in Huntington's disease.

This discovery has a Claude-generated validation package with a full experimental design.

Precise Hypothesis

Spine & Adversarial ReadReady for validation

“This hypothesis tests whether ponatinib directly binds and inhibits the MSH3 ATPase domain via its Walker-A P-loop motif, thereby suppressing MSH3-dependent somatic CAG-repeat expansion at clinically achievable CNS concentrations.”

• highPonatinib is a promiscuous multi-kinase inhibitor with a large, flat, hydrophobic scaffold optimized for kinase ATP-pockets; kinase ATP-binding sites and MSH3's Walker-A P-loop (an ABC/ATPase-family nucleotide fold, structurally distinct from protein kinase folds) are not typically cross-reactive, making the core binding claim structurally implausible without prior computational or experimental evidence presented here.
  The EVP does not yet present preliminary docking, virtual screening hit data, or any prior biochemical signal motivating ponatinib specifically over other kinase inhibitors; this is an unresolved gap that Tier 1 DSF/SPR screening is designed to address, but until that data exists the hypothesis rests on structural analogy/screening plausibility rather than demonstrated evidence.
• highEven if ponatinib inhibits MSH3 ATPase activity biochemically, MutSβ (MSH2-MSH3) ATPase cycling is required for both its mutagenic role in CAG expansion AND its normal mismatch repair function; systemic MSH3 inhibition could increase microsatellite instability/mutagenesis risk elsewhere in the genome, and this safety/mechanistic tension is not addressed in the protocol.
  Not resolved in this EVP; a genome-wide microsatellite instability assay (e.g., MSI panel in treated cells) should be added as a required safety endpoint before any in vivo or clinical translation is considered.
• mediumWhy these specific methods (DSF/SPR/ATPase assay, patient fibroblasts, small-pool PCR) rather than alternatives like a cell-free repeat-expansion reconstitution assay or CRISPR-based MSH3 activity reporters, and why ponatinib specifically rather than a broader kinase-inhibitor library screen to first establish structure-activity relationship?
  Partially justified: DSF/SPR/ITC and malachite-green ATPase assays are standard, well-validated, low-cost first-pass methods for nucleotide-binding-domain inhibitor characterization, and patient fibroblast/iPSC models with small-pool PCR are the field-standard readout for somatic CAG instability (used in GeM-HD Consortium-adjacent studies). However, the choice of ponatinib as the sole lead compound (rather than a panel of structurally related TKIs to establish SAR) is not justified in the current design and should be added to strengthen mechanistic specificity claims.
• highDocking establishes ATP-pocket binding but NOT MSH3 selectivity. A 2026-07-09 focused re-dock with specificity controls showed PONATINIB binds an unrelated Walker-A P-loop ATPase (adenylate kinase, 1AKE) MORE tightly than MSH3 (ADK -10.72 vs MSH3 -8.33 kcal/mol) and MSH2 more tightly too (-9.02). ATP-competitive binding alone does not imply MSH3-specific engagement in cells.
  MANDATORY selectivity counter-screen (added 2026-07-09 after a focused docking re-check): run the MSH3 ATPase-inhibition assay (SPR/ITC/DSF + enzymatic) IN PARALLEL against >=2 unrelated Walker-A / P-loop ATPases (e.g. adenylate kinase 1AKE, a kinesin motor domain, or Ras GTPase). A hit qualifies as MSH3-SELECTIVE only with a pre-registered >=10-fold IC50/Kd separation favouring MSH3. Potency within 3-fold across the panel refutes MSH3-specific engagement and reclassifies any signal as generic ATP-pocket binding.

Experimental Protocol

ROI Projection

Implementation Sketch

# Tier 1: Biochemical validation
express_purify(MSH3_ATPase_domain, MSH2_MSH3_heterodimer, WalkerA_mutant)
for compound in [ponatinib, control_TKIs]:
    dsf_signal = run_DSF(protein, compound, conc_range=[0.1,100]uM)
    if dsf_signal.shift > threshold:
        kd = run_SPR_or_ITC(protein, compound)
        ic50 = run_ATPase_assay(protein, compound, dose_range=log_scale(0.001,100))
        ic50_mutant = run_ATPase_assay(WalkerA_mutant, compound, dose_range=same)
        specificity_ratio = ic50_mutant / ic50

# Tier 2: Structural validation
if specificity_ratio > 5:
    pose = dock(ponatinib, MSH3_structure_or_homology_model)
    md_trajectory = run_MD(pose, duration=100ns, replicas=3)
    validate_pose_with_alanine_scan(predicted_contacts)

# Tier 3: Cellular validation
if pose_validated:
    cell_lines = [HD_patient_fibroblasts, MSH3_KO_isogenic_control]
    for line in cell_lines:
        for dose in [0, 1, 10, 100]nM:
            treat(line, ponatinib, dose, duration=4-8_weeks)
            repeat_length_dist = measure_CAG_repeats(line, method="long_read_seq")
    expansion_index = compute_expansion_index(repeat_length_dist, baseline)
    stats = mixed_effects_model(expansion_index ~ dose * genotype)